Capecitabine (Oral Cancer Medicine) – Patient Information (Australia)

Capecitabine is a cancer medicine taken by mouth. It is used to treat several types of solid tumours, including colorectal and breast cancers, and in some situations it is used together with other medicines. This page explains what capecitabine is, how it works, how it behaves in the body, what to expect during treatment, and important safety and interaction information for people in Australia.

Always follow the instructions provided by your treating healthcare team. Information below is general and may not cover all individual circumstances.

Basic Product Information

Brand availability: Capecitabine may be supplied under different brand names in Australia. Your pharmacist can confirm the specific product and tablet strength you have.

How Capecitabine Works (Mechanism of Action)

Capecitabine is designed to become active in the body. It is a “prodrug” of 5-fluorouracil (5‑FU).

• Capecitabine is absorbed and then metabolised through several steps.
• In tissues—particularly within tumour tissue—capecitabine is converted into active substances that interfere with DNA and RNA production.
• The active drug disrupts the enzymes involved in nucleotide synthesis and can also affect RNA processing, which helps slow down or stop cancer cell growth.
• Because rapidly dividing cells are more sensitive to these effects, tumour cells are targeted while healthy tissues may also be affected (which is why side effects occur).

In plain language: capecitabine helps stop cancer cells from growing by interfering with how they make and use genetic material.

Pharmacokinetics (How the Body Handles Capecitabine)

Pharmacokinetics describe what the body does to a medicine—absorption, distribution, metabolism, and elimination. Key points include:

• Absorption: Capecitabine is absorbed after oral administration.
• Activation: It is metabolised to intermediates and then to 5‑FU inside the body; tumour tissues tend to have more activity of the converting enzyme, which may help target the effect.
• Distribution: The active metabolites distribute through body tissues; binding to plasma proteins may occur for certain metabolites.
• Elimination: Metabolites are excreted primarily through the kidneys.
• Half-life: Half-life values vary by metabolite and are influenced by kidney function and other factors.

Kidney function matters: Because elimination depends partly on the kidneys, dosing and safety monitoring often need adjustment in people with impaired renal function.

Typical Uses in Cancer Treatment

Capecitabine is used for specific cancer types, depending on the stage of disease and your treatment plan. Common indications include:

• Breast cancer: Often used in situations such as adjuvant therapy (after surgery) or for advanced disease, including when in combination regimens are appropriate.
• Colorectal cancer: Treatment of metastatic colorectal cancer and/or adjuvant or other specific settings, depending on clinical guidance and regimen.
• Combination therapy: Capecitabine may be used with other agents (for example, in certain colorectal or gastric/upper GI regimens, as determined by your oncology team).

Your healthcare team will choose the regimen based on factors like cancer type, prior treatments, overall health, and laboratory results.

How to Take Capecitabine (Timing and Practical Use)

Capecitabine is usually taken in cycles (a planned schedule that includes days of taking the tablets and days off). Exact timing depends on the regimen you are prescribed.

Typical schedule approach (example)

• Many regimens use a pattern such as two times daily for a set number of days, followed by a rest period.
• The number of days “on treatment” can vary between regimens.
• Your oncology team will provide the precise day-by-day schedule.

How to take the tablets

• Take your doses at the times you were instructed.
• Swallow tablets whole with water—do not crush or chew unless your pharmacist or doctor specifically instructs you to.
• Use one strength and number of tablets that matches your prescribed total dose for each administration time. If you receive different strengths, your pharmacist will help you understand the correct tablet combination.

If you miss a dose

• Do not take extra tablets to make up for a missed dose unless your clinician instructs you to.
• Contact your treatment team or pharmacist for advice, especially if the missed dose occurs close to the next scheduled dose.

Food Interactions (What to Eat and When)

Food can affect capecitabine absorption. Many clinical protocols specify taking capecitabine within a defined relationship to meals.

• Common instruction: Take capecitabine after food (often after morning and evening meals) to reduce stomach upset and improve absorption.
• Try to keep timing consistent from day to day (e.g., always after breakfast and after dinner).
• If you experience nausea or stomach discomfort, talk to your healthcare team—they may suggest supportive medicines or dietary strategies.

If your product label or your treating team has given different instructions, follow their advice.

Alcohol and Medicine Interactions

Alcohol

There is no single universal “safe amount” of alcohol for all people taking capecitabine, but alcohol may:

• Increase risk of dehydration or worsen fatigue.
• Irritate the stomach and worsen nausea or diarrhoea.
• Affect liver function tests or overall tolerance to treatment.

Practical guidance: If you choose to drink alcohol, keep it minimal and discuss it with your oncologist. Many people receiving chemotherapy prefer to avoid alcohol to reduce side effects and support hydration and nutrition.

Medicine interactions

Capecitabine can interact with other medicines by affecting metabolism or increasing side effects. Important interaction categories include:

• Warfarin and other anticoagulants: Capecitabine may increase bleeding risk by affecting warfarin levels. Close INR monitoring is essential if you use warfarin.
• Phenytoin: Co-administration can alter phenytoin levels (risk of toxicity or reduced seizure control).
• Folinic acid (leucovorin) and other fluoropyrimidines: Some combination regimens can change toxicity risk.
• Allopurinol: May affect metabolism pathways; discuss before use.
• Vaccines and infections: Not a direct drug interaction, but chemotherapy can affect immunity—your clinician may recommend vaccination timing adjustments.

Always tell your pharmacist and oncology team about:

• All prescription medicines
• Over-the-counter medicines
• Herbal products and supplements
• Recent changes to your medication list

Dosing (General Information)

The dose of capecitabine is individual and based on a combination of factors, most commonly:

• Body surface area (BSA) (calculated from height and weight), and/or
• Regimen (which cancer type and combination therapy are being used), and/or
• Kidney function and blood test results

Important: Do not change your dose without guidance. Treatment may require dose reductions or temporary interruptions to manage side effects such as diarrhoea, mouth sores, low blood counts, or hand-foot syndrome.

What may change during treatment

• Dose reductions due to toxicity (e.g., persistent diarrhoea, significant skin changes, or severe fatigue)
• Treatment delays if blood counts are too low or if you are recovering from side effects
• Supportive medications to prevent or manage common adverse effects

How your care team monitors dosing

Monitoring typically includes:

• Regular blood tests (full blood count, kidney and liver function)
• Assessment of symptoms (including mouth, skin, stomach and bowel effects)
• Review of any other medications and new symptoms

Indications (When Capecitabine Is Considered)

Capecitabine is used in certain cancer treatment settings as determined by evidence-based clinical guidelines and specialist oncology decisions. Indications commonly include:

• Colorectal cancer (including metastatic disease in appropriate settings)
• Breast cancer (including adjuvant and advanced disease settings depending on pathology and treatment history)
• Other gastrointestinal cancers in specific regimens where capecitabine is part of standard-of-care approaches

Your oncologist will confirm the specific goal of treatment (for example, curative intent in early-stage disease vs disease control in advanced settings) and the planned cycle schedule.

Safety Profile (Common and Serious Side Effects)

Like all chemotherapy medicines, capecitabine can cause side effects. Many are manageable, but some require urgent medical attention.

Common side effects

• Diarrhoea
• Nausea and vomiting
• Stomach pain or loss of appetite
• Mouth sores (stomatitis)
• Fatigue and weakness
• Hand-foot syndrome (also called palmar-plantar erythrodysaesthesia): redness, swelling, pain, or peeling of skin on hands and feet
• Skin rash
• Low blood counts (may lead to infection risk or anaemia)
• Abnormal liver function tests (identified on blood tests)

Serious side effects – seek urgent care

Contact your treating team urgently or seek emergency care if you experience:

• Severe or persistent diarrhoea (especially with dehydration)
• Fever or signs of infection, including chills and feeling very unwell
• Shortness of breath or chest pain
• Severe mouth sores preventing fluids
• Severe hand-foot syndrome with blistering or inability to use hands or walk
• Signs of allergic reaction (swelling of face/lips, widespread rash, trouble breathing)

Risk factors

• Kidney impairment may increase exposure and risk of toxicity.
• Older age may increase vulnerability to side effects.
• Other medicines can increase toxicity or change blood levels.
• Genetic factors (such as variations affecting drug metabolism) may increase the risk of severe toxicity in some patients.

Your oncologist may consider these factors when selecting dose and monitoring frequency.

Practical Use Tips (What Helps Day-to-Day)

Preventing or reducing hand-foot syndrome

• Moisturise hands and feet regularly with fragrance-free creams recommended by your care team.
• Avoid friction and pressure—wear comfortable footwear and protective socks.
• Avoid hot water on affected skin and limit activities that cause repeated impact (e.g., long walks, heavy lifting).

Managing diarrhoea safely

• Start treatment for diarrhoea early if your clinician has provided instructions for antidiarrhoeal medicines (e.g., loperamide) and hydration plans.
• Drink fluids regularly—oral rehydration solutions can help.
• Avoid dehydration; contact your team if diarrhoea is persistent or severe.

Supporting nutrition and hydration

• Small, frequent meals can be easier if appetite is reduced.
• Choose bland, easy-to-digest foods during nausea or stomach upset.
• If you develop mouth sores, use soft foods and avoid spicy/acidic items.

Blood test and appointment planning

• Attend scheduled blood tests and review appointments on time.
• Keep a symptom diary (e.g., diarrhoea frequency, pain, skin changes) to help your team adjust treatment promptly.

Infection prevention

• Practice good hygiene (handwashing, avoiding sick contacts when possible).
• Report fever immediately—chemotherapy can increase infection risk when blood counts are low.

Alternative Options (Discuss With Your Oncologist)

If capecitabine is not suitable or if side effects become difficult to manage, oncology teams may consider alternatives based on your cancer type and stage, prior treatment history, and tolerance. Alternatives may include:

• Other chemotherapy agents used for colorectal or breast cancers (e.g., fluoropyrimidine-based or non-fluoropyrimidine regimens)
• Infusional 5‑FU regimens or other combination protocols
• Targeted therapies for selected tumour biomarkers
• Hormonal therapy for hormone receptor-positive breast cancer (when appropriate)

The best alternative depends heavily on the individual situation. Your treating team can discuss options and expected benefits and risks.

Capecitabine in the Australian Market: Practical and Legal Context

In Australia, access to cancer medicines like capecitabine is provided through established healthcare pathways. Availability depends on the specific product brand, manufacturing supply, and therapeutic supply arrangements.

• Medicines are typically supplied via pharmacy dispensing systems and require prescribing and dispensing in line with Australian healthcare regulations.
• Oncology care commonly involves close coordination between the treating specialist, GP (where relevant), and pharmacy.
• Pharmacists can assist with dosing instructions, side-effect prevention strategies, and medication reconciliation to reduce interaction risks.

Important: Do not share capecitabine with others. Cancer medicines have individualized dosing and monitoring requirements.

Recent Guidance and Monitoring (What to Expect)

Guidance for capecitabine use can evolve based on clinical research, safety data, and updates to cancer management practices. In Australia, treatment decisions are generally aligned with evidence-based clinical recommendations and specialist oncology protocols.

While recommendations can vary by regimen and cancer type, common “current practice” themes include:

• Early recognition of toxicity to reduce serious complications (e.g., prompt diarrhoea management).
• Regular lab monitoring to detect changes in blood counts and kidney function.
• Dose individualisation based on tolerability and organ function.
• Supportive care (antiemetics, skin care strategies, hydration guidance) to maintain quality of life.

Your oncology team may also use additional monitoring based on your personal history and the exact regimen being followed.

Delivery and Availability (Online Pharmacy Information for Australia)

Online pharmacies in Australia typically handle supply in one of two ways:

• Direct dispatch: Stock is supplied from a pharmacy warehouse and dispatched to your address.
• Order sourcing: If a specific brand or strength is not currently in stock, it may be sourced through the distribution network to meet demand.

Availability can vary by tablet strength and brand. To help ensure timely delivery:

• Confirm the exact tablet strength(s) and the number of tablets per dose time.
• Place your order early enough to allow for processing and transport.
• Keep track of treatment dates so you do not run out between cycles.

Cold chain: Capecitabine tablets typically do not require refrigeration under normal conditions; store as directed on the package and avoid heat and moisture.

Storage and Handling

• Store tablets in their original packaging.
• Keep away from heat, moisture, and direct sunlight.
• Keep out of reach of children.
• Do not use tablets past their expiry date.

If you have questions about storage or returning unused tablets, ask your pharmacist.

FAQ – Capecitabine

1) What is capecitabine used for?

Capecitabine is used to treat certain cancers, commonly including colorectal and breast cancers, in specific settings and regimens determined by oncology specialists.

2) How is capecitabine taken?

It is taken as oral tablets. Many regimens require dosing twice daily and taking the medicine after food. Exact schedules depend on the treatment plan provided to you.

3) What should I do if I miss a dose?

Do not take extra tablets to compensate. Contact your pharmacist or oncology team for advice on what to do based on your schedule and how long ago the dose was missed.

4) Does capecitabine cause hand-foot syndrome?

Hand-foot syndrome is a known side effect. Early skin care, moisturising, and avoiding friction or pressure can help reduce severity. Report changes promptly so dose adjustments can be considered if needed.

5) What foods should I avoid?

There is no single universal “forbidden food,” but taking capecitabine in relation to meals matters (often after food). If you experience nausea, diarrhoea, or mouth sores, your team may recommend dietary adjustments.

6) Can I drink alcohol while on capecitabine?

Alcohol may worsen dehydration, nausea, and stomach irritation. It’s best to discuss alcohol use with your oncologist. Many patients choose to minimise or avoid alcohol during treatment.

7) Are there interactions with common medicines?

Yes. For example, capecitabine may interact with anticoagulants (such as warfarin) and some anti-seizure medicines (such as phenytoin). Always provide your full medication list to your pharmacist.

8) How will I know if the medicine is working?

Response is usually assessed by your oncology team using clinical review, blood tests (where appropriate), and imaging studies or other tumour assessment methods scheduled during treatment.

9) What monitoring will I need?

Regular blood tests and symptom review are typical to monitor blood counts and kidney/liver function and to detect side effects early.

10) Is capecitabine the same as 5‑fluorouracil?

No. Capecitabine is an oral prodrug that is converted in the body into active 5‑FU. The dosing schedules and side-effect profiles may differ depending on the formulation and regimen.

Important Safety Reminder

If you experience severe diarrhoea, fever, significant infection symptoms, severe mouth sores, or worsening hand-foot skin reactions, seek urgent medical advice. For ongoing daily concerns, contact your pharmacy or treating team promptly—early management can prevent complications and may allow treatment to continue safely.